Search

Current filters:
Add Filter:

Results

Customise results display
Item hits:
Issue DateTitleAuthor(s)
2013-12-01Are the true impacts of adverse events considered in economic models of antineoplastic drugs? a systematic reviewPearce, A; Haas, M; Viney, R
2016-10-01Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast CancerParkinson, B; Viney, R; Haas, M; Goodall, S; Srasuebkul, P; Pearson, SA
2010-12-01Nursing takes time: Workload associated with administering Cancer Protocolsde Raad, J; van Gool, K; Haas, M; Haywood, P; Faedo, M; Gallego, G; Pearson, S; Ward, R
2019-03-01Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non–Small Cell Lung Cancer Using Real-World DataHolleman, MS; Uyl-de Groot, CA; Goodall, S; van der Linden, N
2000-01A clinical model for quality of life assessment in cancer patients receiving chemotherapy.Klee, MC; King, MT; Machin, D; Hansen, HH
2012-11-22Chemotherapy administration: Modelling the costs of alternative protocolsHaywood, P; De Raad, J; Van Gool, K; Haas, M; Gallego, G; Pearson, SA; Faedo, M; Ward, R
2014-01-01Cetuximab in locally advanced squamous cell carcinoma of the head and neck: Generalizability of EMR 062202-006 trial resultsVan Der Linden, N; Van Gils, CWM; Pescott, CP; Buter, J; Uyl-De Groot, CA
2019-09-03Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparisonVargas, C; Balmaceda, C; Rodríguez, F; Rojas, R; Giglio, A; Espinoza, MA
Results 1-8 of 8 (Search time: 0.119 seconds).
  • previous
  • 1
  • next